07:52 AM EDT, 03/23/2026 (MT Newswires) -- Bausch + Lomb ( BLCO ) , up 5% in New York trading, Monday announced positive 24-month results from the U.S. clinical trial of the Elios system, which involved 318 patients.

Developed to treat elevated intraocular pressure (IOP) in patients with open angle glaucoma, Elios is an implant-free procedure that uses excimer laser technology. The system met the study's co-primary effectiveness endpoints, demonstrating both statistically significant and clinically meaningful IOP reduction, according to the company.

Key results included unmedicated diurnal IOP (DIOP), which refers to 24-hour eye pressure, was reduced by 20% or greater in 76% of patients. Eighty-two percent of patients were medication-free at 23 months, and no intraoperative complications were seen during the Elios procedure.

"These strong U.S. study results reinforce everything we've learned about ELIOS during the years it has been available in Europe," said Yehia Hashad, chief medical officer. "Achieving meaningful reductions in intraocular pressure and freedom from medication for a majority of patients speaks to the promise of this technology."

Elios is currently approved for use in Europe, but has not been reviewed by the FDA.

Bausch + Lomb ( BLCO ) is up US$0.79 to US$16.51, in U.S. pre-market trading.